• Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Science
    • Quatramer
  • Investors
  • Contact Us
Hillstream
  • Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Science
    • Quatramer
  • Investors
  • Contact Us
    Loading posts...

  • February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers

    Please join us on R & D Day 8:00 AM - Targeting Ferroptosis to Iron Out Resistant Cancers
    February 22, 2022
    Announcement

Recent Posts

  • Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
  • Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer
  • In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer
  • Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
  • Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers

Address:

245 Main St., Ste. 204
Chester, NJ

Tel: +1 (917) 214-3514
Mail: info@hillstreambio.com
Hillstream Biopharma

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807

Tel: 1-908-955-3140
Mail: info@hillstreambio.com

Latest News

  • Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule February 15, 2023
  • Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer February 13, 2023
  • In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer February 10, 2023

© Copyright 2022. Hillstream Biopharma, Inc. All Rights Reserved